ReviewCancers2022
Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases.
Marianna Mekhaeil et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this papercites it
ReviewCancers2022
Marianna Mekhaeil et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.